Deininger M, Szumlanski C L, Otterness D M, Van Loon J, Ferber W, Weinshilboum R M
Department of Pharmacology, Mayo Medical School/Mayo Foundation/Mayo Clinic, Rochester, MN 55905.
Biochem Pharmacol. 1994 Nov 29;48(11):2135-8. doi: 10.1016/0006-2952(94)90515-0.
Thiopurine methyltransferase (TPMT) catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG). A genetic polymorphism regulating TPMT activity in human tissue is an important factor responsible for individual differences in the toxicity and therapeutic efficacy of these drugs. Because of the clinical importance of this polymorphism, we studied 18 purine derivatives, including ribonucleosides and ribonucleotides, as potential substrates for purified human kidney TPMT. Sixteen of the compounds studied were substrates for the enzyme, with Km values that varied from 29.1 to 1270 microM and with Vmax values that varied from 75 to 2340 U/mg protein. The thiopurines tested had Km values that were uniformly lower than were those of the corresponding ribonucleosides or ribonucleotides. 6-Selenopurine derivatives had the lowest Km values of the compounds studied. Finally, oxidized purines with an OH in the 8-position were methylated by the enzyme, but 2-OH compounds were potent inhibitors of TPMT.
硫嘌呤甲基转移酶(TPMT)催化硫嘌呤类药物如6-巯基嘌呤(6-MP)和6-硫鸟嘌呤(6-TG)的S-甲基化反应。人类组织中调节TPMT活性的基因多态性是导致这些药物毒性和治疗效果个体差异的重要因素。鉴于这种多态性的临床重要性,我们研究了18种嘌呤衍生物,包括核糖核苷和核糖核苷酸,作为纯化的人肾TPMT的潜在底物。所研究的化合物中有16种是该酶的底物,其Km值在29.1至1270微摩尔之间变化,Vmax值在75至2340 U/mg蛋白之间变化。所测试的硫嘌呤的Km值始终低于相应的核糖核苷或核糖核苷酸的Km值。6-硒嘌呤衍生物在所研究的化合物中具有最低的Km值。最后,8位带有OH的氧化嘌呤可被该酶甲基化,但2-OH化合物是TPMT的强效抑制剂。